ArticleJournal of biochemical and molecular toxicology2026
P53 Inhibition Diminishes IGSF9 Gene Activity to Promote DNA Repair and Exacerbate the Progression of Colon Cancer.
Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- P53 Inhibition Diminishes IGSF9 Gene Activity to Promote DNA Repair and Exacerbate the Progression of Colon Cancer.Journal of biochemical and molecular toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Colon cancer (CC) is a malignancy with high global incidence and mortality, and elucidating its underlying molecular mechanisms is critical for improving prognostic assessment and therapeutic strategies. In this study, transcriptomic data from a large cohort of CC samples and a limited number of normal controls from the TCGA database were used to construct a multigene prognostic risk model using univariate Cox and least absolute shrinkage and selection operator (LASSO) regression analyses. The expression of key prognostic genes, including immunoglobulin superfamily member 9 (IGSF9), was further validated in CC tissues by PCR and Western blotting. Functional assays were performed in HCT116 cells to investigate the biological effects of IGSF9 overexpression and its regulatory relationship with p53. The prognostic model identified IGSF9 as a gene significantly associated with patient survival. Although IGSF9 expression was reduced at both the mRNA and protein levels in CC tissues, its overexpression in vitro markedly promoted apoptosis, alleviated DNA damage, and suppressed cell migration and invasion. Notably, silencing of p53 partially reversed the tumor-suppressive effects induced by IGSF9 overexpression, indicating that IGSF9 exerts its biological functions in a p53-dependent manner. Collectively, these findings demonstrate that IGSF9 acts as a tumor suppressor in colorectal cancer and regulates DNA damage responses and apoptosis through a mechanism partially dependent on p53, highlighting its potential value as a prognostic biomarker and therapeutic target in CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.